3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
2
Interventions
pembrolizumab
42
Carboplatin
38
Cisplatin
34
Paclitaxel
27
Pemetrexed
23
Gemcitabine
23
Nivolumab
22
Dexamethasone
17
Ipilimumab
16
Rituximab
15
Fluorouracil
14
Capecitabine
14
Docetaxel
13
trastuzumab deruxtecan
12
durvalumab
12
atezolizumab
12
Cyclophosphamide
12
Trastuzumab
11
Lenalidomide
11
olaparib
10
130-nm albumin-bound paclitaxel
10
Prednisone
9
venetoclax
8
daratumumab
8
Oxaliplatin
8
Cytarabine
8
Bortezomib
8
Bevacizumab
8
zanubrutinib
7
Vinorelbine
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Has announcements
×
Pluvicto
×
Clear all
NCT04689828
2026-03-23
PSMAfore
Novartis
Phase 3
Active not recruiting
469 enrolled
11 charts
1 FDA
NCT03511664
2025-01-13
VISION
Endocyte
Phase 3
Completed
861 enrolled
39 charts
1 FDA